quinoxalines has been researched along with yf 476 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allison, B; Barrett, TD; Cagnon, L; Figueroa, K; Freedman, J; Ghoos, E; Lagaud, G; Li, L; Moreno, V; Morton, MF; Prendergast, CE; Pyati, J; Rabinowitz, MH; Rizzolio, MC; Shankley, NP; Ver Donck, L; Wu, X | 1 |
| Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Pathuri, G; Rao, CV; Ritchie, R; Singh, A; Stratton, N; Suen, C | 1 |
2 other study(ies) available for quinoxalines and yf 476
| Article | Year |
|---|---|
JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
Topics: Administration, Oral; Animals; Benzodiazepinones; Biological Availability; Caco-2 Cells; CHO Cells; Cricetinae; Cricetulus; Dogs; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Male; Mice; Phenylurea Compounds; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Species Specificity; Sulfonamides | 2011 |
Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention.
Topics: Adenocarcinoma; Animals; Benzodiazepinones; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Chemoprevention; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Quinoxalines; Receptor, Cholecystokinin B; Signal Transduction; Sulfonamides | 2019 |